Printer Friendly

Controlled Substances Market Key Trends in Terms of Volume and Value 2018-2028.

[170 Pages Report] Controlled Substances Market research report categorizes the global market by Drug Class (Opioids, Stimulants, Depressants, Marijuana), By Application (Attention-Deficit/Hyperactivity Disorder, Pain Management, Depression, Seizure, Anxiety, Sleep Disorders, Cough Suppression, Others), By Distribution Channel (Institutional Sales, Retail Sales), & By Region.

[USPRwire, Thu Aug 22 2019]

Worldwide sales of the controlled substances closed in on a valuation of US$ 67,000 Mn in 2018, and are projected to record a Y-o-Y growth at 3.5% in 2019, according to a new Fact.MR study. The study opines that depressants and stimulants have been top-selling class of drugs in the controlled substances market, however gains from marijuana are expected to record over 2X faster growth than all the other controlled substances in 2019 and beyond.

Report Customization can be done at: https://www.factmr.com/connectus/sample?flag=RC&rep_id=2032

Approval of medical marijuana has been on a significant uptick in various states of the US, trailed by the legalization in Canada for both recreational and medicinal use recently. This has tremendously contributed to the popularity of cannabis stocks, alongside efforts of leading controlled substance manufacturers toward eliminating legal barriers and attracting investor interest. The study estimates marijuana sales in 2019 to record a Y-o-Y growth at 9.3% over 2018.

"The Schedule of Controlled Substances currently positions marijuana in Schedule 1 -- the most restrictive one reserved for "high potential for abuse," "lack of accepted safety" and "no accepted medical use" drugs. Federal scheduling of marijuana has been a key concern among producers and medical patients alike, despite legalization of cannabis in the US and Canada. The US Drug Enforcement Administration has recently removed cannabidiol from Schedule 1, post-FDA approval of non-synthetic, cannabis-derived medicine. Marijuana businesses have cheered the DEA's action, as it alludes the beginning of regulatory relaxation to the cannabis industry," according to a lead analyst at Fact.MR.

Get the Sample PDF of the Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=2032

The study opines that pain management will continue to account for over one-fourth share of the controlled substances market in 2018. Several regulatory norms being implemented in the prescription of controlled substances for pain management, such as in Georgia, Michigan, and Florida, have further triggered the preference and adoption of controlled substances to manage and treat chronic as well as acute pain. Attention deficit hyperactivity disorder (ADHD), and anxiety are other medical conditions wherein controlled substances are expected to witness promising future prospects, according to the study.

The entrance of pharmaceutical giants in the cannabis sector of Canada alludes the next significant trend in the controlled substances industry, offering additional credibility to the sector. Although the pharmaceutical part of the expression involves the missing link, an ongoing trend of M&A and entrance of these legacy industries is poised in 2019 and the foreseeable future. There has been a drought in direct investments from the pharmaceutical industries in the licensed medical marijuana producers, it is highly likely that the trend would change, as the US witnesses the federal legalization of cannabis. Big pharmaceutical companies that eye collaborations and partnerships with cannabis producers having competitive differentiation circling their R&D initiatives, commercialization efforts, and clinical trial programs, are likely to witness significant revenue generation in the near future.

Report Summary of the Report: https://www.factmr.com/report/2032/controlled-substances-market

About Us

Fact.MR's methodology is robust and comprehensive. We employ a range of tools and assets to develop an all-encompassing coverage of a range of industries. We compile data points at local, country, regional, and global level -- our approach to capturing the finest nuances, without losing sight of the bigger picture helps us in developing accurate and reliable forecasts and estimates.

Fact.MR has a standard set of guidelines and standards that help maintain a level of consistency across all of our research offerings. The standardization includes step-by-step documentation of the methodologies and guidelines on the sources that are to be used for incorporation of objective and accurate data.

The standardization also involves use of industry-wide analytical tools, and rigorous quality checks to validate market forecasts and sizes. Our unwavering focus on standardization ensures that clients receive the same quality of research and analysis that Fact.MR is known for.

Contact Us

FactMR Suite 9884 27 Upper Pembroke Street, Dublin 2, Ireland Tel: +353-1-4434-232 Tel: +353-1-6111-593 Email: sales@factmr.com Blog: https://theheraldmedia.com/

Copyright [c] 2019 USPRwire Provided by SyndiGate Media Inc. ( Syndigate.info ).
COPYRIGHT 2019 SyndiGate Media Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:USPRwire
Date:Aug 23, 2019
Words:747
Previous Article:Instrument Calibrator Market: Preeminent Companies Embrace Portable Calibrator to Propel Modus Opera.
Next Article:Bridge Cable Sockets Market Volume Forecast and Value Chain Analysis 2017-2028.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters